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Small-cell lung cancer (SCLC) has an ominous prognosis despite
being susceptible to both chemotherapy and radiotherapy. Median
survival of patients affected by extensive disease ranges between 8
and 11 months, with minimal or no chances of long-term survival
(Ihde, 1984). Chemotherapy of extensive SCLC results in a
response rate of 60–70%; a complete response is obtained in
10–30% of cases. Three chemotherapy regimens are widely used
to treat SCLC: CAV (cyclophosphamide, adriamicin, vincristine)
(Feld et al, 1984), CDE (cyclophosphamide, doxorubicin, etopo-
side) (Aisner et al, 1986) and PE (cisplatin, etoposide) (Einhorn,
1986). The three regimens produce similar response rates. 
Carboplatin, as single agent, was successfully used to treat
SCLC in the mid 1980s (Smith and Evans, 1985; Jacobs et al,
1987). Two randomized trials showed that there was no difference
in terms of efficacy between carboplatin-containing and cisplatin-
containing polychemotherapy (Kosmidis et al, 1994; Lassen et al,
1996). Thanks also to its lower toxicity, carboplatin has become
the most widely used drug in combination with etoposide (Smith
et al 1987; Evans et al, 1988; Bishop, 1992). 
Various newer drugs are under investigation: topotecan (Schiller
et al, 1998), vinorelbine (Gridelli et al, 1998), gemcitabine (Cormier
et al, 1994) and paclitaxel. The latter, as a single agent, resulted in a
53% response rate in patients with extensive-stage SCLC (Ettingen
et al, 1995). Paclitaxel has been associated with either carboplatin or
cisplatin and, in 3-drug regimens, with etoposide (Hainsworth et al,
1997; Glisson et al, 1999). Carboplatin plus paclitaxel has proved
successful as second-line treatment (Groen et al, 1999). There are no
studies on the first-line use of this combination. 
The aim of our study was to evaluate whether carboplatin plus
paclitaxel is sufficiently active in the treatment of adult patients
with extensive SCLC to warrant comparative trials with standard
regimens. 
PATIENTS AND METHODS 
Study design 
We conducted a multicentre phase 2 trial, the main outcome being
response rate. A lowest acceptable probability of response (p0) of
0.50 and a desired probability of response (p1) of 0.70 were used to
calculate sample size. With a type I error of 0.05 and a type II error
of 0.10, at least 31 objective responses out of 50 patients were
required to proceed to phase III testing. The trial was approved by
the ethics committees of the participating institutions. 
Eligibility criteria 
Patients aged 65 years or less were eligible for the trial if they had
a cytological or histological diagnosis of extensive SCLC and a
performance status less than or equal to 2 on the ECOG scale.
Patients previously treated with chemotherapy or radiotherapy or
with a history of another type of cancer (with the exception of non-
melanomatous skin cancer and in situ radically resected cervix
cancer) were excluded. Normal bone marrow, kidney, liver and
heart function were prerequisites for trial entry. Patients with
asymptomatic brain metastases were not excluded. All patients
gave their written informed consent to the study. 
Basal evaluation consisted of clinical examination, haemato-
logical and biochemical assessment and cardiological evaluation
with ECG. Staging procedure consisted of 2-view chest X-ray;
brain, chest, abdomen contrast enhanced CT-scans; radionuclidic
bone scan with X-ray details of hot spots. 
Carboplatin plus paclitaxel in extensive small cell lung
cancer: a multicentre phase 2 study 
C Gridelli1, L Manzione2, F Perrone3, E Veltri4, R Cioffi5, M Grazia Caprio6, L Frontini7, A Rossi1,2, E Barletta1, 
ML Barzelloni1, D Bilancia2 and C Gallo8
1Oncologia Medica B, Istituto Nazionale Tumori, Naples; 2Oncologia Medica, Ospedale S. Carlo, Potenza; 3Ufficio Sperimentazioni Cliniche Controllate, Istituto
Nazionale Tumori, Naples; 4Oncologia Medica, Ospedale S. Maria Goretti, Latina; 5Pneumologia Oncologica, Ospedale Civile, Caserta; 6Oncologia Medica, Az.
Ospedaliera Rummo, Benevento; 7Oncologia Medica, Ospedale S. Paolo, Milan; 8Statistica Medica, Seconda Università, Naples 
Summary A multicentre phase 2 trial (single-stage design) was undertaken to test the efficacy and toxicity of carboplatin (AUC 6 according to
Calvert) plus paclitaxel (175 mg/m2 3-h infusion) every 4 weeks in the first line treatment of patients affected by extensive small cell lung
cancer. The primary end-point of the trial was the objective response rate. 31 objective responses among 50 patients were considered
necessary to proceed to a phase 3 trial. 48 patients were enrolled (median age 59 years). Treatment was very well tolerated. 3 patients (6.2%)
had a complete response and 23 (47.9%) a partial response, for an overall response rate of 54.2% (95% CI: 39.2–68.6). Median time to
progression was 5.7 months (95% CI: 5.2–6.2). Median survival was 9.6 months (95% CI: 7.2–14.6), with a median follow-up time of alive
patients of 12 months. At 1 year, the probability of being progression-free or alive was 0.16 and 0.43, respectively. In conclusion, carboplatin
plus paclitaxel as given in the present study is very well tolerated but not sufficiently active to warrant phase 3 comparison with standard
chemotherapy regimens. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: paclitaxel; carboplatin; small cell lung cancer 
38
Received 17 May 2000 
Revised 15 August 2000 
Accepted 13 September 2000 
Correspondence to: C Gridelli 
British Journal of Cancer (2001) 84(1), 38–41
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1541, available online at http://www.idealibrary.com on  http://www.bjcancer.comDrug schedule 
Carboplatin was given i.v. to reach a dose of AUC 6, diluted in
250 cc normal saline solution in 30 min on day 1; paclitaxel was
given i.v. at a dose of 175 mg/m2, diluted in 500 cc normal saline in
a 3-h infusion on day 1. Creatinine clearance was either measured
or calculated with the Jelliffe formula (Jelliffe, 1997); the carbo-
platin dose was calculated according to Calvert’s formula (Calvert
et al, 1989). Antiemetic medication consisted of 5HT3 antagonists
(at a standard dose) on day 1. 30 min before paclitaxel, patients
were given 20 mg dexamethasone plus 100 mg ranitidine plus 50
mg prometazine i.v. 
Cycles were repeated every 4 weeks for a maximum of 6 times.
Dose reductions were not planned. Cycles could be delayed
up to 2 weeks in case of neutrophils <1.500 mm c–1 or platelets
<100 000 mm c–1 on the day of planned treatment. Treatment was
stopped in cases of a delay of 2 weeks and persisting toxicity.
Response was evaluated at the end of the third cycle, and only
responding patients remained on treatment. Investigators were free
to decide whether or not to administer prophylactic G-CSF. 
Calculation of dose parameters 
To verify patients’ compliance to the treatment schedule, dose
parameters were calculated for paclitaxel alone. The total deliv-
ered dose of paclitaxel is the sum of the single delivered doses.
Time-on-treatment is the interval between day 1 of the first cycle
up to day 28 of the last cycle. Delivered dose-intensity is the ratio
between total delivered dose and time-on-treatment, and is
expressed as mg/m2 week–1.Relative dose-intensity of paclitaxel is
the ratio between delivered dose-intensity and planned dose-
intensity (43.75 mg/m2 week–1). 
Scales for toxicity and response assessment 
The WHO graded scale (Miller et al, 1981) was used to score toxi-
city; scoring of fatigue and headache were revised a posteriori and
codified according to the Common Toxicity Criteria of the
National Cancer Institute of Canada (version 2.0). Toxicity was
assessed before each cycle of chemotherapy. Toxicity was assessed
on the worst data for each patient across all cycles of
chemotherapy. Objective responses were evaluated according to
the WHO scale (Miller et al, 1981) at the end of chemotherapy
cycles 3 and 6 by repeating staging procedures. The best response
was recorded for each patient. Response evaluation was antici-
pated in case of clinically evident or suspected disease progres-
sion. The objective response rate is the proportion of complete plus
partial responses on all patients. 
Statistical analysis 
For response rate, we calculated (Geigy Scientific Tables) 95%
exact binomial confidence intervals (CI). We used contingency
tables to evaluate the association between the patients’ baseline
characteristics and objective response (coded as binary variable:
no/yes), and the chi-square test to test statistical significance, 
using test for trend for PS and number of neoplastic sites. Fisher’s
exact test was used to test association of toxicity with G-CSF
administration. Progression-free survival was defined as the
interval between day 1 of cycle 1 up to progression of disease or
death, whichever occurred first. Overall survival was calculated as
the interval between day 1 of cycle 1 and date of death or date of
the last follow-up visit. Progression-free and overall survival 
curves were estimated with the Kaplan-Meier product limit
method (Kaplan and Meier, 1958); the 95% CI of median values
were calculated according to Brookmeier and Crowley (BMDP
Statistical Software, Los Angeles, CA, University of California
Press, 1992). 
RESULTS 
From March 1997 to October 1999, 48 patients (males: 87.5%)
entered the trial (Table 1). Median age was 59 years (range 36–65).
Performance status was impaired in most patients (14.6% were in
EOCG category 0 and 66.7% in category 1). 4 patients had asymp-
tomatic brain metastases at entry. No patient had received previous
chemotherapy or radiotherapy. The median number of neoplastic
sites was 3 (range 1–5). 25 (52.1%) patients received all the plan-
ned 6 cycles of treatment. Treatment was stopped because of pro-
gressive disease in 14 (29.2%) patients, toxicity in 2 (4.2%) and
refusal in 7 (14.6%). Prophylactic G-CSF from cycle 1 was given
to 17 (35.4%) patients. Another patient required G-CSF because of
grade 4 neutropenia at the first cycle; this patient also received
prophylactic G-CSF in subsequent cycles. 
The median relative delivered dose-intensity (RDDI) of pacli-
taxel was 0.99 (range 0.83–1.19). There was a deviation from the
protocol in 2 patients, i.e., recycling treatment was given every 21
instead of 28 days. There was no difference (P = 0.52) in the
median RDDI between patients who did not receive prophylactic
G-CSF (n = 30, mean RDDI = 0.98) and those who did (n = 18,
mean RDDI = 1.01). 
Overall, toxicity was mild (Table 2); only two patients stopped
treatment because of toxicity. One patient had grade 4 hepatic toxi-
city after cycle 4. This patient had grade 1 hepatic toxicity during
cycles 2 and 3, but had recovered before the subsequent dose of
chemotherapy. Another patient developed allergy after administra-
tion of cycle 1. 
There was no difference in incidence and degree of toxicity
between patients receiving and those not receiving prophylactic 
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Table 1 Characteristics of patients (n = 48) 
Sex, No. (%) 
Male 42 (87.5%) 
Female 6 (12.5%) 
Age, years 
Median 59 
Range 36–65 
ECOG performance status score, No. (%) 
0 7 (14.6) 
1 32 (66.7) 
2 9 (18.8) 
Brain metastases, No. (%) 
No 44 (91.7) 
Yes (asymptomatic) 4 (8.3) 
Previous radiotherapy, No. (%) 
No 48 (100) 
Neoplastic sites, No. (%) 
1 2 (4.2) 
2 9 (18.8) 
3 22 (45.8) 
4 14 (29.2) 
5 1 (2.1) 40 C Gridelli et al
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G-CSF, with the exception of grade 2–3 thrombocytopenia, which
occurred only in patients receiving G-CSF (P = 0.05). 
3 patients (6.2%) had a complete response and 23 (47.9%) a partial
response (Table 3), resulting in an overall response rate of 54.2%
(95% exact CI: 39.2–68.6). Sex, age and performance status did not
affect the probability of response (data not shown). The number of
disease sites was correlated (P = 0.04) with response: the rate of
responder patients decreased from 72.7% to 59.1% and 33.3% in
patients with <3, 3 and >3 sites of disease, respectively. 
Second-line chemotherapy was given to 13 patients out of 48. 
8 of the 13 patients had partially responded to initial chemo-
therapy, 3 had had a stabilization and 2 had progressed while on
treatment. Second-line chemotherapy consisted of combination
treatment in 2 cases (ifosfamide + vinorelbine and carboplatin +
epirubicin + etoposide, 1 case each) and single agent treatment in
11 cases (topotecan 6 cases, etoposide 3 cases, epirubicin 1 case,
vinorelbine 1 case). One partial response was obtained (in the
patient receiving the triplet regimen, who had also responded to
first-line treatment) and one disease stabilization with topotecan,
in a patient who had progressed while on first-line treatment. 
As shown in Figure 1, as of March 2000, 43 patients (89.6%) had
progressed and 33 (68.7%) had died. Median time-to-progression
was 5.7 months (95% CI: 5.2–6.2). Median survival was 9.6
months (95% CI: 7.2–14.6); the median follow-up time of alive
patients was 12 months. At 1 year, the probability of being
progression-free or alive was, respectively, 0.16 and 0.43. 
DISCUSSION 
We found that carboplatin plus paclitaxel is very well tolerated
but not sufficiently active to warrant phase 3 comparison with
standard chemotherapy regimens for extensive SCLC. 
A possible explanation for this negative result is that the dose-
intensity of both drugs in our study was lower compared with
schedules commonly used in such solid tumours as non-SCLC and
ovarian cancer. The low dose-intensity is primarily due to
recycling every 4 weeks. In addition, the paclitaxel dose per cycle
is in the lower range of doses administered as 3-h infusion in the
treatment of other solid tumours. 
We elected to test a non-aggressive scheme so as not to deteriorate
the patients’ quality of life. At present, patients with extensive SCLC
have no chance of being cured, little chance of prolonged survival and
urgent need of palliation with treatment well balanced in terms of effi-
cacy and toxicity. To our knowledge there are no publications about
carboplatin plus paclitaxel as first-line treatment for extensive-stage
SCLC patients. However, our results could be expected from two 
abstracts presented at the 1999 Congress of the American Society of
Clinical Oncology. Thomas and colleagues (1999) studied a regimen
theoretically more intensive than ours (AUC 6 carboplatin and
200 mg/m2 paclitaxel as 3-h infusion given every 3 weeks); data
reported for 35/46 enrolled patients showed a response rate of 67%,
10% complete responses and a median survival of 6 months.
Deppermann et al (1999) using the same schedule as Thomas et al
obtained a 61% response rate in 75 patients, with 7% complete
responses and a median survival of 12 months. Toxicity was impor-
tant in the latter study: grade 3–4 neutropenia in 43% of cycles and
grade 2–3 peripheral neurotoxicity in 29% of cycles. Our results are
consistent with these two abstracts, except toxicity was less frequent
and severe in our study. 
Our data differ from those reported by Groen et al (1999) who
studied the same combination (AUC 7 carboplatin plus 175 mg/m2
paclitaxel as 3-h infusion every 3 weeks) as second-line treatment
in 34 SCLC patients, most of whom had responded to a previous
CDE regimen. Groen and colleagues obtained an impressive 73.5%
response rate (with 6% complete responses) and a median survival
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Figure 1 Kaplan-Meier estimated progression-free and overall survival curves
Table 2 Worst grade of toxicity 
Toxicity (grade) No. (%) of patients 
Leukopenia (4) – 
Neutropenia (4) 1 (2.1) 
Thrombocytopenia (2–3) 3 (6.3) 
Anaemia (2–3) 4 (8.3) 
Infections (3) 1 (2.1) 
Vomiting (2–3) 6 (12.5) 
Diarrhoea (2) 1 (2.1) 
Oral mucositis (2) 2 (4.2) 
Fatigue (2–3) 15 (31.3) 
Headache (grade 3) 1 (2.1) 
Allergy (1–2) 2 (4.2) 
Skin (1) 1 (2.1) 
Fever (1) 1 (2.1) 
Cardiac (1) 1 (2.1) 
Respiratory (1–2) 3 (6.3) 
Renal (1) 1 (2.1) 
Hepatic (4) 1 (2.1) 
Constipation (1) 6 (12.5) 
Peripheral neurotoxicity (1–2) 3 (6.3) 
Central nervous system (1) 1 (2.1) 
Hair loss (2–3) 20 (41.7) 
Table 3 Objective results 
Outcome No. (%) 95% CI 
Objective response 
Complete response 3 (6.2) 
Partial response 23 (47.9) 
Stable disease 8 (16.7) 
Progressive disease 11 (22.9) 
Restaging not performeda 3 (6.2) 
Response rate 26 (54.2) 39.2–68.6 
Progressed patients 43 (89.6%) 
Median time-to-progression (months) 5.7Carboplatin plus paclitaxel in extensive SCLC 41
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exceeding 7 months. The selection of patients with a positive 
prognostic factor (sensitivity to previous chemotherapy) and other
unknown selection biases might explain this divergence. However,
ours being a phase 2 study design, we cannot exclude a false-
negative result. Nevertheless, our data together with earlier studies
(Deppermann, 1999; Thomas, 1999) indicate that the association
of paclitaxel with platinum compounds in 2-drug combinations is
not a good candidate for phase 3 trials. 
A promising approach might be to add paclitaxel to standard
drugs, in 3-drug combinations, e.g. carboplatin or cisplatin plus
etoposide plus paclitaxel. Kelly et al (1999), in a phase 1 trial of
paclitaxel plus etoposide plus cisplatin in extensive disease found
that the recommended doses were 175 mg/m2 as 3-h infusion on
day 1 for paclitaxel, 80 mg/m2 i.v. on day 1 and 160 mg/m2 p.o. on
days 2–3 for etoposide, and 80 mg/m2 i.v. cisplatin on day 1, all
recycled every 3 weeks, with support of haemopoietic growth
factors. Out of 28 patients treated at 4 dose levels, an 83%
response rate was recorded with 10 months median survival.
Glisson et al (1999), in a phase 1–2 study of cisplatin plus etopo-
side plus paclitaxel, which included 41 patients with extensive
SCLC, reported the maximum tolerated dose of the 3 drugs to be
75 mg/m2 day 1, 80 mg/m2 days 1–3, 135 mg/m2 in 3 h day 1,
respectively, all given i.v. every 3 weeks. Responses were
recorded in 90% of patients, and were complete in 16%. In another
phase 2 trial of 117 SCLC patients, carboplatin plus oral etoposide
plus paclitaxel resulted in an impressive response rate of 98% with
complete responses in 71% and median survival not reached at 16
months of follow-up in patients with non-extensive disease. In
cases of extensive disease the response rate was 84%, complete
responses 21% and 10 months median survival. Overall, as
expected, the treatment was very toxic with grade 3–4 neutropenia
in 71% of patients, grade 3–4 thrombocytopenia in 24% and grade
3–4 anaemia requiring transfusion in 35%. These data strongly
suggest that the 3-drug combination needs to be studied in phase 3
comparisons that explore the impact of toxicity on the quality of
life of patients in view of the small survival advantages. 
In conclusion, the 2-drug combination with carboplatin plus
paclitaxel should undergo further explorative clinical trials before
it can be recommended for phase 3 testing. 
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